Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilateral ESP Block for Postoperative Pain in Open Abdominal Surgeries
NCT07479069Active, not recruiting
- Sponsor
- Fatima Memorial Hospital
- Start
- Oct 2025
- Primary completion
- Mar 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised trial of ropivacaine hydrochloride liposomal suspension injection and bupivacaine hydrochloride 0.75% injection in postoperative pain (2 arms), sponsored by Fatima Memorial Hospital. Primary endpoint: Postoperative Opioid Consumption at 24 hours. Started Oct 2025; status: active, not recruiting.
02
Drugs
ropivacaine hydrochloride liposomal suspension injectionbupivacaine hydrochloride 0.75% injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT07479069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07479069.